Mats Blom
Vorsitzender bei EGETIS THERAPEUTICS AB
Vermögen: 2 Mio $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas Meyer | M | 56 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | 21 Jahre |
Helén Tuvesson | M | 62 | 26 Jahre | |
Alf Gunnar Martin Nicklasson | M | 69 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 13 Jahre |
Alain Munoz | M | 75 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | 6 Jahre |
Margrit Schwarz | M | 60 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | 3 Jahre |
Thomas Lönngren | M | 73 | 3 Jahre | |
Nicklas Westerholm | M | 48 | 7 Jahre | |
Emanuel Björne | M | 51 | 17 Jahre | |
Laetitia Szaller | F | - | 1 Jahre | |
Hilary Malone | M | 59 | 3 Jahre | |
Vincenza Nigro | F | - | 6 Jahre | |
Gunilla Christina Osswald | M | 63 | 7 Jahre | |
Morris J. Birnbaum | M | 72 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 2 Jahre |
Lena Elisabeth Svanberg | M | 63 | 7 Jahre | |
David A. Fraser | M | - |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Ivan M. Møller | M | 52 | 6 Jahre | |
Covadonga Pañeda | M | 51 | - | |
Stephanie Kenney | F | - | 2 Jahre | |
Eva Nilsagård | F | 60 | 5 Jahre | |
Andreas Eggert | M | 56 | 6 Jahre | |
Yilmaz Mahshid | M | 45 | 3 Jahre | |
Søren Tulstrup | M | 59 | 6 Jahre | |
Karl Hård | M | 62 | 2 Jahre | |
Anders Gersel Pedersen | M | 73 | 6 Jahre | |
Peter Nicklin | M | 61 | 2 Jahre | |
Kirsten Drejer | M | 68 | 6 Jahre | |
Hans Kolam | M | 73 | 24 Jahre | |
Peder Sven Walberg | M | 50 | 4 Jahre | |
Hilde Hermansen Steineger | M | 58 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 7 Jahre |
Matthew Shaulis | M | - | 1 Jahre | |
Marianne Berrens-Peijnenburg | M | - | 2 Jahre | |
Anne Lanner | F | 55 | 5 Jahre | |
Anna Sjögren | F | 56 | - | |
Nils Hallén | M | 56 | 1 Jahre | |
Peter Verwaijen | M | - | 2 Jahre | |
Kristina Nygren | - | - | 3 Jahre | |
Christian Sonesson | M | 49 | 7 Jahre | |
Hitto Kaufmann | M | 53 | 1 Jahre | |
Jordi Xiol | M | - |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 3 Jahre |
Max Sakajja | M | 43 | 7 Jahre | |
Richard Gaster | M | 40 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 4 Jahre |
Marcel Gremaud | M | 66 | 3 Jahre | |
Samuel Wickline | M | 71 | 3 Jahre | |
John Kastelein | M | 70 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Dirk Kersten | M | 49 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Rob de Ree | M | - |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Malin Nittve | F | 61 | - | |
Katayoun Welin-Berger | M | 56 | 1 Jahre | |
Klaus Sindahl | M | - | 5 Jahre | |
Hugo Slootweg | M | 53 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 7 Jahre |
Achim Kaufhold | M | 66 | 4 Jahre | |
Henrik Krook | M | 51 | 4 Jahre | |
Magnus Korsgren | M | 55 | 3 Jahre | |
Marie Bengtson | F | - | 13 Jahre | |
Armando Anido | M | 66 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | 8 Jahre |
Henk Doude van Troostwijk | M | - | 8 Jahre | |
Søren Møller | M | 56 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Somu Subramaniam | M | 69 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Jonathan Leff | M | 66 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jacques Näsström | M | 65 | 13 Jahre | |
Tomas Leanderson | M | 68 | 18 Jahre | |
Ulf Arne Wiinberg | M | 66 | 6 Jahre | |
Hernan Levett | M | 49 | 2 Jahre | |
John Hyttel | M | 78 | 15 Jahre | |
Mats Georg Arnhög | M | 73 | 19 Jahre | |
Stein Revelsby | M | 62 | 11 Jahre | |
Hanne Leth Hillman | F | 59 | 5 Jahre | |
Catherine Moukheibir | F | 64 | 5 Jahre | |
Rosemary Crane | F | 64 | 4 Jahre | |
Göran Forsberg | M | 61 | - | |
Dan Wahrenberg | M | 55 | 10 Jahre | |
Michael Owen | M | 73 | 12 Jahre | |
David Solomon | M | 63 | 7 Jahre | |
Britt Meelby Jensen | F | 51 | 4 Jahre | |
Angelica Loskog | M | 51 | 3 Jahre | |
Raoul F. Dias | M | - | - | |
Rasmus Just | M | 48 | 14 Jahre | |
Helle Størum | F | 57 | 9 Jahre | |
Lani Pollworth Morvan | M | - | 2 Jahre | |
Peter Sjöstrand | M | 78 | 20 Jahre | |
Christian Kjellman | M | 57 | 15 Jahre | |
Jørgen Lindegaard | M | 76 | - | |
Hans Mikael Otterling | M | 63 | - | |
Bo Jesper Hansen | M | 66 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 16 Jahre |
Eva Steiness | M | 83 | 19 Jahre | |
Stina Margareta Gestrelius | M | 75 | 12 Jahre | |
Jutta af Rosenborg | F | 65 | - | |
Karin Hallbeck | F | 68 | - | |
Lena Louise Nilsson | F | 57 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 Jahre |
Katja Margell | F | - | 2 Jahre | |
Kennet Rooth | M | 69 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 5 Jahre |
Camilla Gummesson | F | 51 | - | |
Elmar Schärli | M | 52 | 2 Jahre | |
Donato Spota | M | 53 | 5 Jahre | |
Folke Per-Olof Wallström | M | 75 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 Jahre |
Maha Katabi | M | 50 |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 3 Jahre |
Peter Myrenfors | M | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 3 Jahre |
Claes E. Wilhelmsson | M | 85 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 6 Jahre |
Helle Haxgart | F | 62 | 1 Jahre | |
Kerstin Edung | F | - |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweden | 61 | 61,00% |
Dänemark | 17 | 17,00% |
Niederlande | 13 | 13,00% |
Bermuda | 9 | 9,00% |
Schweiz | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen